Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis

被引:153
作者
Rahman, I
Skwarska, E
Henry, M
Davis, M
O'Connor, CM
FitzGerald, MX
Greening, A
MacNee, W
机构
[1] Univ Edinburgh, Royal Edinburgh Infirm, Dept Med, Resp Med Unit, Edinburgh EH10 5HF, Midlothian, Scotland
[2] Univ Coll Dublin, Dept Med & Therapeut, Dublin 2, Ireland
[3] Western Gen Hosp, Resp Med Unit, Edinburgh, Midlothian, Scotland
关键词
oxidants; antioxidants; lipid peroxides; glutathione; smoking; idiopathic pulmonary fibrosis; free radicals;
D O I
10.1016/S0891-5849(99)00035-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An oxidant/antioxidant imbalance has been proposed in patients with idiopathic pulmonary fibrosis (IPF). We tested this hypothesis by measuring various parameters of the oxidant/antioxidant balance in the plasma of 12 patients with IPF (7 nonsmokers and 5 smokers); in the bronchoalveolar lavage fluid (BALF) of 24 patients with IPF (17 nonsmokers and 7 smokers) and 31 healthy subjects (23 nonsmokers and 8 smokers). The trolox equivalent antioxidant capacity (TEAC) in plasma and BALF was lower in nonsmoking patients with IPF (plasma 0.55 +/- 0.1 mM, p < .001; BALF 4.8 +/- 1.2 mu M, mean +/- SEM, p < .01), compared with healthy nonsmokers (plasma 1.33 +/- 0.03 mM; BALF 10 +/- 2 mu M). Similar trends in plasma and BALF TEAC were observed in smoking patients with IPF in comparison with healthy smokers. The decrease in BALF TEAC was concomitant with a decrease in BALF protein thiol levels, but the decrease TEAC levels in plasma in IPF patients was not accompanied by a decrease in protein thiol levels. Reduced glutathione (GSH) was lower in BALF in nonsmoking patients with IPF (1.0 +/- 0.1 mu M) compared with healthy nonsmokers (2.3 +/- 0.2 mu M, p < .001). In contrast, GSH levels were higher in smoking patients with IPF (5.2 +/- 1.1 mu M, p < .001) than in nonsmoking patients. GSSG levels were not different in any of the groups. The levels of products of lipid peroxidation measured as thiobarbituric acid reactive substances (TBARS) in plasma and BALF were significantly increased in both smoking (plasma 2.2 +/- 0.5 mu M, p < .01; BALF 0.18 +/- 0.04 mu M, p < .001), and nonsmoking (plasma 2.1 +/- 0.3 mu M, p < .01; BALF 0.22 +/- 0.05 mu M, p < .001) IPF patients, compared with healthy nonsmokers (plasma 1.4 +/- 0.3 mu M; BALF 0.05 +/- 0.004 mu M). These data show evidence of oxidant/antioxidant imbalance in the lungs of patients with IPF, which is also reflected as systemic oxidant stress. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:60 / 68
页数:9
相关论文
共 43 条
[11]   TISSUE SULFHYDRYL GROUPS [J].
ELLMAN, GL .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1959, 82 (01) :70-77
[12]   CYTOKINES .4. CYTOKINES AND PULMONARY FIBROSIS [J].
GAULDIE, J ;
JORDANA, M ;
COX, G .
THORAX, 1993, 48 (09) :931-935
[14]  
HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715
[15]   Serum indicators of free radical activity in idiopathic pulmonary fibrosis [J].
Jack, CIA ;
Jackson, MJ ;
Johnston, IDA ;
Hind, CRK .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (06) :1918-1923
[16]   INCREASED PRODUCTION AND IMMUNOHISTOCHEMICAL LOCALIZATION OF TRANSFORMING GROWTH-FACTOR-BETA IN IDIOPATHIC PULMONARY FIBROSIS [J].
KHALIL, N ;
OCONNOR, RN ;
UNRUH, HW ;
WARREN, PW ;
FLANDERS, KC ;
KEMP, A ;
BEREZNAY, OH ;
GREENBERG, AH .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1991, 5 (02) :155-162
[17]  
KING TE, 1988, INTERSTITIAL LUNG DI, P139
[18]   EFFECT OF CIGARETTE-SMOKE AND ITS CONDENSATES ON ALVEOLAR EPITHELIAL-CELL INJURY IN-VITRO [J].
LANNAN, S ;
DONALDSON, K ;
BROWN, D ;
MACNEE, W .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (01) :L92-+
[19]   Oxidized BAL fluid proteins in patients with interstitial lung diseases [J].
Lenz, AG ;
Costabel, U ;
Maier, KL .
EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (02) :307-312
[20]   AN INVESTIGATION OF THE ROLE OF GLUTATHIONE IN INCREASED EPITHELIAL PERMEABILITY INDUCED BY CIGARETTE-SMOKE IN-VIVO AND IN-VITRO [J].
LI, XY ;
DONALDSON, K ;
RAHMAN, I ;
MACNEE, W .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (06) :1518-1525